Iovance Biotherapeutics, Inc.
999 Skyway Road
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was initially developed by Dr. Steven A. Rosenberg at the National Cancer Institute (NCI). In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology were reported by NCI to have achieved objective and complete response criteria, respectively.
Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.
In addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.
999 Skyway Road
San Carlos, CA 94070
One Crescent Drive, Suite 105
Philadelphia, PA 19112
Stock Symbol: IOVA
150 articles with Iovance Biotherapeutics, Inc.
There has been a spate of recent news regarding the expansion of facilities and the expected job growth for the biopharma and life sciences industry. Here’s a look at some of those stories.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
In an exclusive interview with BioSpace, Iovance CEO Maria Fardis said the company’s goal is to add headcount to support its growth strategy. The company currently has about 100 full-time employees.
The area is home to numerous well-known players in the pharma industry, including Abbott, Iovance, Gossamer Bio, Crown Biosciences, Illumina, Human Longevity and many, many more.
10/29/2018Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
Maria Fardis, chief executive officer of Iovance Biotherapeutics, sees tumor infiltrating lymphocyte (TIL) therapies as the best immunotherapy option to treat solid cancers.
6/26/2018The general consensus is that only about seven to nine percent of chief executive roles in biotech are filled by women. As low as that sounds, it’s better than in the Fortune 500, where only about 4.2 percent are led by female chief executives.
RXi Pharmaceuticals Enters into Material Transfer Agreement with Iovance Biotherapeutics to Study its Self-Delivering RNAi Technology for the Advancement of Immuno-Oncology Therapeutics
Synergies between RXi's self-delivering RNAi (sd-rxRNA®) therapeutic platform and Iovance's TIL cell therapy approach will be explored preclinically
IOVANCE INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Iovance Biotherapeutics, Inc. - IOVA
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. announces that KSF has commenced an investigation into Iovance Biotherapeutics, Inc.
Since Friday, the stock market has been volatile, to say the least.
Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144,
The offering is expected to close on or about January 29, 2018, subject to customary closing conditions.
Iovance intends to use the proceeds from this offering to fund its ongoing clinical trials for its current product candidates, including its ongoing Phase 2 clinical trials of LN-144.
The company also announced that a Phase 2 study in PD-1/PDL-1 naïve NSCLC patients will initiate in the first half of 2018.
Iovance Biotherapeutics Announces Manufacturing Decision, Provides Clinical Updates and Highlights Pipeline Expansion at Analyst Day 2017
Additionally, the company’s proprietary Generation 2 (Gen 2) manufacturing process has now been selected for all ongoing and future TIL clinical development.
BioLife Solutions today announced that it has executed an agreement to supply its CryoStor cell freeze media and HypoThermosol cell storage and shipping media to Iovance Biotherapeutics.
The event will highlight Iovance’s lead clinical programs.
Iovance Biotherapeutics Announces New LN-144 Phase II Clinical Data from Metastatic Melanoma Trial to be Presented at SITC Meeting
The data shows that administration of the company’s Generation 2 (Gen 2) manufacturing process in nine efficacy-evaluable metastatic melanoma patients resulted in a disease control rate (DCR) of 78%, which includes 3 confirmed partial responders (PRs) and a fourth PR awaiting confirmation.
The company will host a conference call at 4:30pm ET today.
Iovance Biotherapeutics to Host Conference Call to Discuss Third Quarter 2017 Financial Results and Provide a Corporate Update on Tuesday, October 31, 2017
Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET.